Compare EXK & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXK | STVN |
|---|---|---|
| Founded | 1981 | 1949 |
| Country | Canada | Italy |
| Employees | N/A | N/A |
| Industry | Precious Metals | Containers/Packaging |
| Sector | Basic Materials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 2004 | 2021 |
| Metric | EXK | STVN |
|---|---|---|
| Price | $10.27 | $15.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $13.94 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 8.7M | 634.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $63.94 | $9.67 |
| Revenue Next Year | $8.76 | $9.99 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.23 | $12.89 |
| 52 Week High | $15.15 | $28.00 |
| Indicator | EXK | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 62.54 |
| Support Level | $8.33 | $14.03 |
| Resistance Level | $10.31 | $16.69 |
| Average True Range (ATR) | 0.54 | 0.57 |
| MACD | 0.18 | 0.27 |
| Stochastic Oscillator | 80.59 | 95.63 |
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.